These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 37943443)

  • 1. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
    Verma S; Mudaliar S; Greasley PJ
    Adv Ther; 2024 Jan; 41(1):92-112. PubMed ID: 37943443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.
    Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M
    Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?
    Popovic DS; Koufakis T; Patoulias D; Papanas N
    Expert Rev Clin Pharmacol; 2023; 16(11):1021-1023. PubMed ID: 37864783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
    Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
    Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.
    Chiriacò M; Tricò D; Solini A
    Curr Opin Pharmacol; 2022 Oct; 66():102272. PubMed ID: 35964531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.
    Mancini GBJ; O'Meara E; Zieroth S; Bernier M; Cheng AYY; Cherney DZI; Connelly KA; Ezekowitz J; Goldenberg RM; Leiter LA; Nesrallah G; Paty BW; Piché ME; Senior P; Sharma A; Verma S; Woo V; Darras P; Grégoire J; Lonn E; Stone JA; Yale JF; Yeung C; Zimmerman D
    Can J Cardiol; 2022 Aug; 38(8):1153-1167. PubMed ID: 35961754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.